Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST‐Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design

Novel therapies capable of reducing myocardial infarct (MI) size when administered prior to reperfusion are required to prevent the onset of heart failure in ST‐segment elevation myocardial infarction (STEMI) patients treated by primary percutaneous coronary intervention (PPCI). Experimental animal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulluck, Heerajnarain, Fröhlich, Georg M., Mohdnazri, Shah, Gamma, Reto A., Davies, John R., Clesham, Gerald J., Sayer, Jeremy W., Aggarwal, Rajesh K., Tang, Kare H., Kelly, Paul A., Jagathesan, Rohan, Kabir, Alamgir, Robinson, Nicholas M., Sirker, Alex, Mathur, Anthony, Blackman, Daniel J., Ariti, Cono, Krishnamurthy, Arvindra, White, Steven K., Meier, Pascal, Moon, James C., Greenwood, John P., Hausenloy, Derek J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2015
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489325/
https://www.ncbi.nlm.nih.gov/pubmed/25990305
http://dx.doi.org/10.1002/clc.22401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489325/
https://www.ncbi.nlm.nih.gov/pubmed/25990305
http://dx.doi.org/10.1002/clc.22401

Ejemplares similares